Skip to content
Search AI Powered

Latest Stories

Cannabis Study Offers Hope for Veterans Battling PTSD

For years, military veterans suffering from post-traumatic stress disorder (PTSD) have sought alternative treatments beyond traditional pharmaceuticals. Now, after years of regulatory hurdles and advocacy, the U.S. Food and Drug Administration (FDA) has approved a groundbreaking Phase 2 clinical trial to study the effects of smoked marijuana on veterans with moderate to severe PTSD.

FDA Approves Landmark Cannabis for PTSD in Veterans - The Bluntness

FDA Approves Landmark Cannabis for PTSD in Veterans - The Bluntness

Photo by Wesley Tingey on Unsplash

For years, military veterans suffering from post-traumatic stress disorder (PTSD) have sought alternative treatments beyond traditional pharmaceuticals. Now, after years of regulatory hurdles and advocacy, the U.S. Food and Drug Administration (FDA) has approved a groundbreaking Phase 2 clinical trial to study the effects of smoked marijuana on veterans with moderate to severe PTSD. Funded by tax revenue from Michigan's legal cannabis sales, this research represents a monumental step toward validating cannabis as a legitimate treatment option for PTSD.

PTSD affects millions of veterans, with many turning to medical marijuana for relief. Anecdotal evidence from veterans suggests that cannabis can alleviate anxiety, improve sleep, and reduce the emotional intensity of traumatic memories. Yet, despite its inclusion in many state-level medical marijuana programs, rigorous clinical data supporting its efficacy has been sparse.


Dr. Sue Sisley, a psychiatrist and the principal investigator for the trial, explains, “Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for life-threatening conditions like PTSD. This study will generate data that doctors, like myself, can use to develop treatment plans that better serve our patients.”

The study aims to assess the real-world effects of inhaled high-THC cannabis flower compared to a placebo. Participants will self-titrate, or adjust their dosage, reflecting how many veterans already consume cannabis. This approach ensures the research mirrors actual usage patterns, making the results more applicable to everyday life.

A Long Road to Approval

The journey to secure FDA approval for this study was anything but smooth. The Multidisciplinary Association for Psychedelic Studies (MAPS), the nonprofit leading the research, faced five clinical hold letters from the FDA over a three-year period. These holds addressed contentious issues, including the proposed THC dosage, the smoking delivery method, and the inclusion of cannabis-naive participants.

In August 2024, MAPS submitted a formal dispute resolution request, arguing that these restrictions hindered meaningful research. The FDA eventually relented, allowing the trial to proceed with commercially available THC levels and requiring participants to have prior experience with inhaled cannabis.

Rick Doblin, founder and president of MAPS, noted, “MAPS takes pride in leading the way to open new research pathways by challenging the FDA to think differently. This study is a critical step in ensuring cannabis research reflects the way people actually use it.”

Veterans Leading the Charge for Cannabis Reform

This trial is not occurring in a vacuum. Veterans have been at the forefront of both medical marijuana and psychedelics reform, advocating for expanded access to treatments that address their unique mental health challenges. Organizations like the Iraq and Afghanistan Veterans of America and the Wounded Warrior Project have consistently pushed for congressional action to fund research and provide clearer pathways to alternative therapies.

State-level initiatives have also bolstered these efforts. Michigan, for example, allocated $13 million from its Veteran Marijuana Research Grant Program to fund this trial, underscoring the state’s commitment to advancing veteran healthcare. Other states, including Massachusetts and California, have explored pilot programs and working groups to investigate the therapeutic benefits of cannabis and psychedelics for veterans.

The Potential Impact of Smoked Cannabis on PTSD Treatment

If successful, this study could fundamentally reshape how PTSD is treated in veterans. Current treatment options, such as antidepressants and antipsychotics, often come with significant side effects, including severe constipation, confusion, and, paradoxically, increased agitation. Many veterans report abandoning these medications in favor of cannabis, which they say provides more immediate and comprehensive relief.

The trial’s unique design—focusing on self-titration and real-world usage—could yield data that is more relevant and actionable than traditional clinical studies. This could pave the way for cannabis to be more broadly integrated into veteran healthcare programs, potentially reducing the reliance on pharmaceuticals that many find ineffective or harmful.

The Potential Impact of Smoked Cannabis on PTSD Treatment - The BluntnessThe Potential Impact of Smoked Cannabis on PTSD Treatment - The Bluntness Photo by Maria Fernanda Pissioli on Unsplash

A Broader Implication for Mental Health Treatment

This study isn’t just about veterans; it’s about challenging the stigma surrounding cannabis as a treatment for mental health conditions. MAPS’s research aligns with a growing body of work exploring the therapeutic potential of psychedelics, including MDMA and psilocybin. While the FDA recently rejected an MDMA-assisted therapy for PTSD, the progress made in these fields reflects a shifting perspective at the federal level.

The approval of this trial highlights the need for nuanced, evidence-based approaches to mental health treatment. As Leith J. States, chief medical officer at the Office of the Assistant Secretary for Health, observed, “We’re moving forward… and we’re doing things in a way that marches us forward in an incremental way.”

Despite this milestone, significant challenges remain. Cannabis-naive participants were excluded from the trial due to safety concerns, potentially limiting the study’s generalizability. Additionally, the FDA has not yet approved the use of vaporization devices, which some veterans prefer over smoking. These limitations highlight the complexities of conducting cannabis research within the framework of federal regulations.

Furthermore, systemic barriers persist. The Department of Veterans Affairs (VA) has been criticized for its slow adoption of cannabis research, with some veterans accusing the agency of “dragging their feet” on exploring alternative treatments. Advocates hope that the success of this trial will accelerate change at the institutional level, ensuring broader access for veterans in need.

A New Era for Cannabis Research

The FDA’s approval of this landmark study signals a new era for cannabis research, one that prioritizes real-world applications and addresses the urgent needs of vulnerable populations. For veterans living with PTSD, this trial represents hope—hope for treatments that honor their experiences and provide genuine relief.

As states like Michigan continue to fund cutting-edge research and as organizations like MAPS challenge outdated regulatory frameworks, the future of medical marijuana looks increasingly promising. This trial is more than just a study; it’s a step toward validating the lived experiences of millions of veterans and reshaping the conversation around mental health treatment.

With millions of dollars invested and countless lives potentially impacted, this trial is a reminder of the power of persistence, advocacy, and evidence-based innovation in transforming healthcare. The road ahead may still be fraught with challenges, but the destination—a world where veterans have access to effective, compassionate care—is worth every step.

More For You

Store your psilocybin mushrooms properly for best results.
Store your psilocybin mushrooms properly for best results.
Photo by Marco Allegretti on Unsplash

Psilocybin 101: How to Store Magic Mushrooms to Maximize Potency and Shelf Life

Magic mushrooms, or psilocybin mushrooms, have been embraced for their transformative effects and potential therapeutic benefits. However, like any organic material, they are perishable and can lose potency—or worse, become unsafe—if not stored correctly. Whether you're healing depression or having trippy sex to hallucinatory entertainment, understanding how to properly store your mushrooms can help you preserve their effects for months or even years.

This comprehensive guide outlines best practices, advanced techniques, and essential tips for safely storing magic mushrooms to maintain their potency and avoid spoilage.

Keep ReadingShow less
How Cannabis is Easing Dementia Symptoms and Changing Lives - The Bluntness
How Cannabis is Easing Dementia Symptoms and Changing Lives - The Bluntness
Photo by Steven HWG on Unsplash

Cannabis: A New Hope for Dementia Care

For decades, dementia has been a formidable challenge for patients, caregivers, and healthcare providers alike. Characterized by anxiety, agitation, and a decline in cognitive function, the disease often leaves loved ones and medical professionals searching for ways to improve patients’ quality of life. Enter cannabis—a once-stigmatized plant now emerging as a potential game-changer for dementia care.

While definitive research is limited, anecdotal evidence and early studies are painting a promising picture of cannabis as a tool for managing symptoms like anxiety, agitation, and sleep disturbances. For patients like 72-year-old Mark Roberts of Elwell, Michigan, cannabis has provided relief traditional medications failed to deliver. “It just calms me down,” he shared with the Wall Street Journal, of the liquid cannabis dose he takes twice a day. His wife Brenda agrees, noting in the article how the treatment has positively impacted their relationship by easing his outbursts and anxiety.

Keep ReadingShow less
Cannabis Edibles: Dosage and Safety Tips - The Bluntness

Cannabis Edibles: Dosage and Safety Tips - The Bluntness

Edible Dosage Tips

As the allure of cannabis edibles grows stronger in our modern culture, it becomes increasingly important to navigate this space with both curiosity and caution. What exactly goes into determining the right dosage of THC, and why is it crucial for both new and experienced users to get it right?

This article aims to unfold the layers of understanding necessary to enjoy cannabis edibles safely and effectively. From the basics of THC and its impact on the body to personalized dosing strategies and safety protocols, we cover essential insights that promise to enhance your experience.

Keep ReadingShow less
Protecting Your Kids from Accidental Cannabis Ingestion - The Bluntness
Protecting Your Kids from Accidental Cannabis Ingestion - The Bluntness
Photo by Patrick Fore on Unsplash

5 Steps to Keep Kids Safe from Cannabis

As cannabis becomes legal in more regions across the U.S. and globally, one critical issue has come to light: the alarming increase in accidental ingestion of cannabis edibles by young children. Between 2017 and 2021, the National Poison Data System recorded over 7,000 cases of cannabis exposure among children under the age of 6, with a 1,375% spike during this period. The vast majority of these cases stemmed from edibles left within the home, often mistaken for regular candies or treats.

Cannabis poisoning in children can result in serious complications, from vomiting and confusion to breathing difficulties, and in many cases, hospitalization. However, there are ways to minimize the risk of accidental ingestion and the severity of its effects. This article offers a thoughtful, research-backed approach to safeguarding your children and reducing the potential harms of cannabis exposure.

Keep ReadingShow less
DEA prohibited from randomly searching passengers at airports and other transport hubs - The Bluntness

DEA prohibited from randomly searching passengers at airports and other transport hubs - The Bluntness

Photo by Jusdevoyage on Unsplash

No More DEA Traveler Searches!

Republished from NORML with permission.

Agents affiliated with the US Drug Enforcement Administration (DEA) have been instructed to stop searching travelers at airports or other “mass transportation facilities” without a warrant, following a directive issued by Justice Department’s Office of the Inspector General. The directive, issued earlier this month, followed an investigation by the IG’s office. That investigation determined that DEA personnel lacked adequate training and often failed to properly document their search-related activities.

“The DEA’s failure to collect data for each consensual encounter, as required by its own policy, and its continued inability to provide us with any assessment of the success of these interdiction efforts once again raise questions about whether these transportation interdiction activities are an effective use of law enforcement resources – and leaves the DEA once again unable to provide adequate answers to those questions,” Inspector General Michael E. Horowitz determined.

Keep ReadingShow less